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Neurobiology of Disease

The Expression of MicroRNA miR-107 Decreases Early in
Alzheimer’s Disease and May Accelerate Disease Progression
through Regulation of ␤-Site Amyloid Precursor ProteinCleaving Enzyme 1
Wang-Xia Wang,1* Bernard W. Rajeev,1* Arnold J. Stromberg,2 Na Ren,2 Guiliang Tang,3 Qingwei Huang,1
Isidore Rigoutsos,5 and Peter T. Nelson1,4
1

Sanders-Brown Center on Aging, 2Department of Statistics, 3Department of Plant Sciences, and 4Department of Pathology and Division of Neuropathology,
University of Kentucky, Lexington, Kentucky 40536, and 5Bioinformatics and Pattern Discovery Group, IBM Thomas J. Watson Research Center, Yorktown
Heights, New York 10598

MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.
However, little is understood about the role(s) of miRNAs in Alzheimer’s disease (AD). We used miRNA expression microarrays on RNA
extracted from human brain tissue from the University of Kentucky Alzheimer’s Disease Center Brain Bank with near-optimal clinicopathological correlation. Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented
with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD. Among the AD-related miRNA
expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of
pathology. In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression. Computational analysis predicted that the 3⬘-untranslated
region (UTR) of ␤-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107. From the same
RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on
nondemented, MCI, and AD patients. BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell
culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological
miR-107 miRNA recognition sequence in the 3⬘-UTR of BACE1 mRNA. Together, the coordinated application of miRNA profiling,
Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be
involved in accelerated disease progression through regulation of BACE1.
Key words: Alzheimer’s; miRNAs; microarray; in situ; BACE; noncoding

Introduction
MicroRNAs (miRNAs) are small regulatory RNAs with potent
roles in metabolism, neurodevelopment, neuroplasticity, apoptosis, and other fundamental neurobiological processes (for review, see Nelson et al., 2003; Kosik and Krichevsky, 2005).
miRNAs exert their function through base-pairing with specific
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“target” mRNAs with partially complementary sequences, resulting in decreased polypeptide formation from those mRNAs (Ambros, 2004). Depending on the algorithm used, bioinformatics
predict that miRNAs regulate from 30% of human genes (Lewis
et al., 2003, 2005) to as much as 92% (Miranda et al., 2006).
The study of miRNA biology is in its infancy, particularly in
the human brain. Researchers have shown that RNA is pathologically altered in Alzheimer’s disease (AD) brains (Ginsberg et al.,
1997; Honda et al., 2005; Ding et al., 2006; Nelson and Keller,
2007). However, a role for miRNAs in the progression of AD has
not been established firmly. Previous studies demonstrated that a
subset of miRNAs show altered expression in advanced AD, and
these changes may be stimulated by reactive metal elements in the
brain (Lukiw, 2007; Lukiw and Pogue, 2007). These previous
studies in AD brains were limited in the number of miRNAs that
were evaluated.
Expression profiling has provided important insights into
miRNA biology. Microarray studies have helped to describe
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which miRNAs are expressed during vari- Table 1. Cases used with neuropathological correlation
ous normal and abnormal brain states, inTemporal cortex
Pathology
Counts
cluding in brain diseases (Babak et al.,
Diffuse plaques
Neuritic plaques
NFT
Braak stage
PMI (h)
Age
2004; Ciafre et al., 2005; Nelson et al.,
Case 1
47
15
17
6
3.5
87
2006; Perkins et al., 2007). Although AD
Case 2
34
16
31
6
3
93
miRNA expression analyses can provide
Case 3
50
30
31
6
3.33
84
groundbreaking data for this novel reCase 4
38
23
11
6
2.33
75
search field, miRNA profiling benefits
Case 5
18
22
35
6
4.5
84
from the parallel use of more than a single
Case 6
50
20
14
6
2.75
90
40
21
23
6.0
3.2
85.5
technique. Previous work confirmed that Average
understanding cellular level expression
Case 1
7
9
1
3
2.45
97
patterns is vitally important for brain MCI
Case 2
47
12
0
3
5
91
miRNA studies (Nelson et al., 2006). In
Case 3
0
0
0
3
2.75
93
situ hybridization (ISH) pinpoints exactly
Case 4
50
9
1
4
3.5
87
where specific miRNAs are expressed:
Case 5
22
14
0
3
2.9
82
Case 6
50
5
5
5
2
99
neurons, astrocytes, oligodendrocytes,
29
8
1
3.5
3.1
91.5
microglia, and/or vasculature. Neurode- Average
generative diseases tend to affect distinct
Nondemented
Case 1
4
6
0
1
4
91
cell populations. Hence, knowing which
with SMT
Case 2
3
0
0
0
3.25
92
miRNAs are expressed in which cell popuplaques
Case 3
37
9
0
2
2.75
93
lations can facilitate the identification of
Case 4
17
2
0
2
2.4
87
Case 5
3
2
0
0
3.5
95
disease-relevant miRNA genes and their
Average
13
4
0
1.0
3.2
91.6
mRNA targets.
␤-Site amyloid precursor proteinNondemented
Case 1
0
0
0
2
1.66
85
cleaving enzyme 1 (BACE1) is a proteinwithout SMT
Case 2
0
0
0
1
5
88
coding gene known to be important in AD.
plaques
Case 3
0
0
0
1
2.25
80
BACE1 protein is an endopeptidase that
Case 4
0
0
0
1
1.75
86
Case 5
0
0
0
2
4
90
cleaves the ␤-amyloid precursor protein to
Case 6
0
0
0
1
2
76
generate neurotoxic ␤-amyloid peptide
Average
0
0
0
1.3
2.8
84.2
A␤1– 42 (Vassar et al., 1999; Haniu et al.,
2000). The dysregulation of BACE1 may Cases used for miRNA microarray involved detailed evaluation, both prior and subsequent to patients’ death. Brain samples were obtained immediately
to tissue that was used for detailed neuropathological evaluation. ⬙Pathology counts⬙ represent a quantitation of neuropathological lesions as
play a major role in the pathogenesis of AD subjacent
described in detail previously (Nelson et al., 2007). SMT signifies the superior and middle temporal gyri. Note that, in these areas, there is a graded increase
(Dominguez et al., 2004; Durham and in pathology between the four groups. NFT, Neurofibrillary tangle.
Shepherd, 2006; Guo and Hobbs, 2006;
John, 2006). BACE1 is enriched in neutemporal cortex and separately from motor cortex. Subjacent tissue was
evaluated neuropathologically for all samples. Tissue (4 – 8 g) that had
rons (Bigl et al., 2000; Fukumoto et al., 2002) and its expression is
been snap-frozen in liquid nitrogen and then transferred to a ⫺80°C
regulated posttranscriptionally (Marambaud et al., 1998; Rossner
freezer was thawed in isotonic lysis buffer with RNasin (160 U/ml; Proet al., 2006). However, BACE1 gene expression regulation is not
mega, Madison, WI) and Complete protease inhibitor tablets (Roche,
completely understood. Here, we provide data indicating that
Indianapolis, IN). Tissue was homogenized for 5 min on ice using a glass
miR-107 contributes to BACE1 posttranscriptional regulation
and Teflon hand homogenizer followed by additional disruption with a
and that this pathway is predicted to exacerbate pathology in AD
Microson XL2000 hand sonicator (Fisher Scientific, Waltham, MA)
brains.

Materials and Methods
RNA isolation from a human cerebral cortex. RNA was extracted from
snap-frozen brain tissue from the University of Kentucky Alzheimer’s
Disease Brain Bank under a University of Kentucky Institutional Review
Board protocol. Premortem clinical evaluations were exhaustive, and the
last cognitive evaluation was performed usually within the last year of life
as described previously (Schmitt et al., 2000). Clinical diagnoses were
established at Consensus Conference with University of Kentucky neuropsychologists, neurologists, and neuropathologists. The inclusion criteria that we applied were as follows: postmortem interval (PMI) ⬍5 h,
no argyrophilic grains, no cortical Lewy bodies, no evidence of frontotemporal dementia, no cancer in the brain parenchyma, and no infarctions within 3 cm of the brain tissue samples. These neuropathological
confounds were assessed using standard neuropathological procedures
as described in detail previously (Nelson et al., 2007). Demented controls
were from the brains of patients with dementia with Lewy bodies (DLB),
in comparison with “pure” AD that lacked Lewy bodies. Five DLB patients were of ages 68, 82, 85, 87, and 90 years. Braak stages for these
patients were 2 or 3. Before RNA extraction, meninges and large vessels
were removed; gray matter was dissected away from white matter, and
only gray matter was used for these studies.
RNA was isolated from brain tissue cut from superior and middle

(three times 10 s each on ice), and then the samples were centrifuged at
16,000 ⫻ g for 15 min at 4°C. The supernatant was used for RNA isolation. Trizol LS (Invitrogen, Carlsbad, CA) was used according to manufacturer’s instructions, except for an additional overnight ⫺20°C precipitation step during isopropanol precipitation. RNA quality was
confirmed using A260/A280 readings as well as banding pattern and RNA
Integrity Number using an Bioanalyzer (Agilent, Palo Alto, CA); degraded samples were discarded.
Microarray methods and analyses. The miRCURY Labeling kit (Exiqon,
Woburn, MA) was used for target labeling and hybridization to a conventional miRNA microarray. The oligonucleotide probe arrays were
printed on Codelink substrates, processed, and scanned at the University
of Pennyslvania Microarray Core Facility. Detailed methods with regard
to miRNA labeling and hybridization are provided in supplemental file 1
(available at www.jneurosci.org as supplemental material).
cDNA microarrays: Affymetrix Exon Arrays. RNA for the cDNA microarrays was from the same temporal isocortex samples as used for the
miRNA microarray. Samples used were from AD (n ⫽ 3), mild cognitive
impairment (MCI) (n ⫽ 4), and nondemented (n ⫽ 4) brains. The
mRNA reverse transcription, labeling, hybridization, and other processing were performed exactly as written in the Affymetrix (Santa Clara, CA)
technical manual. Exon Array data were also processed using the Affymetrix Expression Console software, and using that software, normal-
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Figure 1. miRNA expression for a subset of miRNAs from temporal (superior and middle gyri)
cortex. Note that miR-107 levels are decreased significantly already in MCI cases and trends
toward a decrease in nondemented patients with incipient pathology. Although case-to-case
variance is considerable, a trend is clearly discernible for miR-107. miR-26a was chosen for
comparison because this miRNA has the closest expression to miR-107 on our microarray and
was subject to very similar global normalization parameters. Hence, ordinate values are the
same for A and B. The horizontal bars are the average for that condition. *p ⬍ 0.005; **p ⬍
0.03, Student’s one-tailed t tests.
ization was performed by using the gene level analysis, core annotation
confidence, median polish summarization method, and global median
normalization method.
Validation: in situ hybridization, Northern blots, and Western blots. The
seven different cases used for ISH were not the same as the cases used for
any of the RNA expression profiling. For ISH, brain tissue from the
following were used: AD case 1, 80-year-old female, Braak stage 6; AD
case 2, 93-year-old female, Braak stage 5; AD case 3, 75-year-old male,
Braak stage 6; nondemented case 1, 92-year-old male, Braak stage 0;
nondemented case 2, 85-year-old female, Braak stage 0; nondemented
case 3, 77-year-old male, Braak stage 4 (pathology “probable AD”); demented control with multiinfarct dementia related to cerebral amyloid
angiopathy and an anomalous pattern of neurofibrillary pathology, 87year-old male.
ISH was performed as described previously (Nelson et al., 2006) with
modifications. Tissue was obtained at autopsy, placed into 4% paraformaldehyde, and fixed for 24 –36 h at 4°C. Tissue was then placed in 20%
sucrose overnight, again at 4°C. The following day, tissue was cut on a
freezing microtome at 25 m thickness and mounted onto coated glass
slides (VWR, West Chester, PA). After air-drying for 30 min, slides were
stored at ⫺80°C. For in situ hybridization, sections were first allowed to
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equilibrate to room temperature and then treated with Proteinase K
(Roche; 40 g/ml) for 20 min at room temperature, followed by quenching with glycine (Fisher Scientific; 1 mg/ml for 15 min). After PBS
washes, slides were immersed in 10% formaldehyde (Fisher Scientific; 10
min), washed again twice in PBS, and treated with acetic anhydride/
triethanolamine (Fisher Scientific; 10 min) at room temperature. Sections were then washed in PBS (four times, 10 min each) followed by 5⫻
SSC (twice, 5 min each). Prehybridization was performed for 3 h at 37°C
is in a buffer prepared thus: 650 ml of ultrapure formamide [EMD (Omnipur), Gibbstown, NJ]; 250 ml of 20⫻ SSC; 1 ml of Tween 20; and 100
g/ml purified yeast RNA (Roche). LNA probes (Exiqon) were diluted to
1.6 M in prehybridization buffer. Care was taken not to refreeze diluted
LNA probes. For both miR-107 and miR-124 probes, hybridization was
performed at 37°C. After overnight hybridization, which was performed
with mechanical agitation, slides were washed at 37°C (twice with 5⫻
SSC for 5 min, and then three times with 2⫻ SSC in 50% formamide for
20 min each), followed by three washes in PBS with 0.1% Triton X-100
(PBST) at room temperature. Nonspecific antigen blocking was performed at 4°C in PBST with 2% sheep serum (Jackson ImmunoResearch,
West Grove, PA) and 2 mg/ml RNase-free BSA [EMD (Omnipur)] for
2 h, followed by the addition of 1:1000 diluted AP-conjugated antidigoxigenin antibody (Roche) and incubation overnight at 4°C. The next
day, tissue is washed in PBST (four times 10 min each), and then in
staining solution (10 mM Tris-HCl, pH 9, 50 mM MgCl2, 100 mM NaCl,
0.1% Tween 20) twice for 5 min. Nitroblue tetrazolium and bromochloroindoyl phosphate (Roche) at 50 mg/ml each were added, and the
staining reaction was at room temperature with gentle movement for
8 –24 h. miR-24 and miR-204 were used in this application because the
former has nearly identical Tm with miR-107, and miR-204 has low
expression in the CNS and a low Tm.
Northern blots were performed as described previously (Nelson et al.,
2004) with some modifications. The amount of RNA loaded in each well
was normalized to the amount of total RNA and tRNA levels as described
previously (Tang et al., 2007).
For Western blots, 20 g of total protein was loaded onto each lane.
BACE1 monoclonal antibody (R&D Systems, Minneapolis, MN) was
used at 1:1000. ␤-Actin monoclonal antibody (Rockland, Gilbertsville,
PA) was used at 1:1000.
Bioinformatics: rna22-based predictions of putative miR-107 miRNA
targets prediction in BACE1 mRNA 3⬘-untranslated region. To identify a
list of putative gene targets for the microRNAs of interest, we used the
rna22 algorithm described previously (Miranda et al., 2006). One
strength of rna22 is its ability to identify putative microRNA binding sites
along the length of the entire mRNA transcript [i.e., in 3⬘-untranslated
regions (UTRs) as well as 5⬘-UTRs and CDSs]. Moreover, rna22 does not
impose any cross-genome conservation constraints when determining
the targets of a miRNA. For the analyses described below, we focused
only on the 3⬘-UTR of BACE1. Our studies also considered predictions
contained in other publicly available databases of predicted miRNA targets, as described in Results.
Validation: reporter vector constructs, transfection, and dual luciferase
assays. The evaluation of putative miRNA recognition elements (MREs)
in the 3⬘-UTR of mRNAs was performed as described previously (Kiriakidou et al., 2004; Nelson et al., 2004) with modifications. To experimentally test two of the predicted miR-107 MREs in the 3⬘-UTR of
BACE1, reporter vectors bearing these binding sites were subcloned into
the mammalian expression vector pRL-TK (Promega) carrying the Renilla luciferase gene (Rluc) as a reporter. Predicted miR-107 binding
sites, designated B1 (aatttaagtcgggaaattctgctgcttga) and B2 (attcccactgcacttggtgctgctttggc), which reside on BACE1 (NM_012104.3) 3⬘-UTR
between 2208 and 2245 and between 3741 and 3774, respectively, were
inserted into the 3⬘-UTR of Rluc gene at the XbaI and NotI restriction
sites as described previously (Kiriakidou et al., 2004; Nelson et al., 2004).
Mutated MREs (B1mut, aatttaagtcgggaaattcttggccttga; B2mut, attcccactgcacttgcgttgcgtttggc) containing sequence modifications predicted to affect the “seed region” targeted by miR-107 were used as negative controls
such that the overall A/G/C/T nucleotide composition was not changed
between the B1/B1mut or B2/B2mut. To monitor the reporter system,
hsa-Let-7 MRE on LIN28 (LIN28), and its mutated sequence (M2) were
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used for positive and negative controls as de- Table 2. Correlations between the expression of miRNAs and other genes
scribed previously (Kiriakidou et al., 2004; NelR2 correlation coefficient R2 correlation coefficient R2 correlation: other intronic
son et al., 2004). Correct construct sequences Gene(s) assignment
versus miR-107
versus miR-103
miRNAs versus mother mRNAs
were confirmed by sequencing the 3⬘-UTR of
miRNA microarray
Rluc gene on all of the pRL-TK vectors.
miR-103
(⫹) 0.912
HeLa cells (American Type Culture Collection, Manassas, VA) were cultured under the
vendor’s recommended conditions. For the lu- Exon array microarray
NM_148978//PANK1
(⫹) 0.06
(⫹) 0.14
ciferase reporter assay, HeLa cells were plated at
NM_024960//PANK2
(⫺) 0.071
(⫺) 0.061
a density of 4 ⫻ 10 5 per well in a 24-well plate a
NM_024594//PANK3
(⫹) 0.16
(⫹) 0.236
day before transfection. Two separate transfections were performed, because otherwise the
(⫺) 0.11
plasmid and short interfering RNA (siRNA) miR-126 versus EGLF7
(⫹) 0.005
transfections interfered with each other (data miR-128a versus R3HDM1
(⫺) 0.006
not shown). For the first transfection, 0.4 g of miR-342 versus EVL
Rluc-encoding pRLTK reporter plasmid along The degree to which the expression of different miRNAs is correlated with expression of other genes is described for miR-103, miR-107, and other intronic
with 0.2 g Firefly luciferase (Fluc)-encoding miRNAs. The detected expressions of miR-103 and miR-107 are very highly correlated on our microarray, which may represent cross-hybridization. The other
show the correlation between the expression of various miRNAs, using the miRNA microarray, versus the expression of genes in which those
PGL3 (Promega) control plasmid were trans- comparisons
miRNAs are introns (n ⫽ 11 using a Affymetrix microarray as for Fig. 7). miR-107 resides in PANK1; paralogous miR-103 genes are present within PANK2 and
fected using Lipofectamine 2000 reagent (In- PANK3; miR-126 is intronic within EGFL7, as are miR-128a and miR-342 within R3HDM1 and EVL, respectively. The (⫹) preceding the R2 numbers indicates
vitrogen) according to the manufacturer’s in- a positive correlation, whereas (⫺) indicates a negative correlation. None of the correlations between intronic miRNAs and their mother mRNAs were
structions. Transfected cells were washed in statistically significant; an ANOVA to test the significance of the regression between miR-103 and PANK-3 mRNA levels was the lowest at 0.12.
antibiotic-free media after 6 h of transfection,
and the cells were allowed to recover overnight. Twenty-four hours after
the first transfection, cells were further transfected with 250 nM of either
miR-107 siRNA duplex (sequences: agcagcauuguacagggcuauca and
auagcccuguacaaugcugcguu), miR-320 siRNA duplex (sequences:
aaaagcuggguugagagggcgaa and cgcccucucaacccagcuuuguu), or only with
transfection reagent mixture, using siRMAX (Invitrogen) according to
manufacturer’s instructions. Luciferase reporter activity analysis was
performed 24 h after the siRNA transfection using Dual Luciferase Assay
System (Promega) and a Turner 20/20 n luminometer (Fisher Scientific)
according to the manufacturers’ instructions. To control for transfection
efficiency, relative luciferase activity was calculated by normalizing the
RLuc (pRL-TK) to the Fluc (PGL-3) readouts. Each experimental condition was performed in triplicate within individual experiments, and the
results shown represent two independent experiments.

Results
miRNA microarray results
RNA was isolated from patients with different clinical and neuropathological features as shown in Table 1. Note the short PMIs
and the detailed correlation with neuropathology from subjacent
tissue. Cases were separated into four groups: nondemented with
no/negligible AD-type pathology, nondemented with incipient
AD pathology, MCI with moderate AD pathology, and AD. The
expression patterns for most miRNAs were stable across the different clinical states. Approximately 200 different miRNAs were
expressed at levels above background on this array, but only ⬃70
miRNAs were detected at a high enough level to merit comparative studies.
Among the few miRNAs that were consistently changed in AD
versus nondemented brains was miR-107 (Fig. 1). One-way
ANOVA shows that miR-107 shows a highly significant decrease
across the four groups at p ⫽ 0.014. Of particular interest was the
unique decrease between miR-107 levels in nondemented patients without pathology versus MCI (Student’s t test, p ⫽ 0.008),
suggesting that decreased miR-107 expression occurs in the earliest stages of AD.
Other miRNAs differed between nondemented and AD patients but did not appear changed in the subclinical stages of AD.
miR-103 is a close paralog of miR-107, differing only at a single 3⬘
base. The expression of miR-107 was ⬃20% higher than miR103; however, as shown in Table 2, R 2 (correlation coefficient) for
miR-107 and miR-103 readout for the microarray was ⬎0.91.
Because the levels of miR-103 on the microarray closely mirrored
miR-107, the miR-103 signal probably represents cross-

Figure 2. Northern blots were used to validate the microarray data indicating that miRNA
expression changes are seen in early AD pathogenesis. These results show that miR-107 levels
are decreased early in the development of AD, whereas the expression of other miRNAs trend
toward a slight increase. The miRNAs were chosen to represent a gamut of high and mediumexpression level miRNAs.

hybridization as would be expected on a Northern blot. In addition to a decreased expression of miR-107 in temporal cortex, a
trend for decrease in miR-107 was also seen in motor cortex in
AD brains (data not shown) (one-way ANOVA for motor cortex
is p ⫽ 0.050; for motor cortex, n ⫽ 19 different brains were
assessed). These changes seem to indicate global change in brain
miR-107 levels, even in areas less affected by AD pathology.
Among other highly expressed miRNAs, ANOVA analyses indicate that miR-23b was also expressed at lower levels in AD brains
than nondemented brains ( p ⫽ 0.015).
We decided to focus on changes in miR-107 because these
appeared to have the greatest statistical significance and emerged
very early in the progression of the pathology. Demented controls
are important to assess the specificity of the changes seen in AD.
For these controls, isocortex from patients with DLB (n ⫽ 5) were

Wang et al. • Expression of MicroRNA miR-107

J. Neurosci., January 30, 2008 • 28(5):1213–1223 • 1217

ficial layers are stained; however, the
deeper layers show a marked decrease in
miR-107 hybridization (Fig. 4). This decrease of miR-107 in deep layers was observed also in a single nondemented case in
which there was significant AD pathology
(nondemented case 3 in Materials and
Methods with pathology showing probable
AD) (data not shown), an observation that
correlates with the microarray data showing decreased miR-107 expression early in
the pathology (Fig. 1). The cortical lamina
with decreased miR-107 ISH signals coincide with cerebral cortical lamina where the
neuropathological lesions of AD (thioflavine S-positive plaques and tangles) are
seen (Fig. 4). In the perirhinal cortex, an
isocortical (six-layered) region affected
early by AD, ISH was performed on brain
tissue from two elderly nondemented cases
Figure 3. ISH performed on human brains shows that miR-107 is enriched in neurons. A is a photomicrograph of a nondewithout appreciable pathology and commented patient’s hippocampus at low power probed for miR-107 and shows CA1 and CA3 as well as the dentate gyrus (dg). B and
pared with two AD cases (Fig. 5 shows repC show higher-power photomicrographs, from the area boxed in 3A, with miR-107 (B) and miR-124 (C), another neuronenriched miRNA. miR-124 ISH was performed on a near-serial brain section. D, Unlike miR-124, miR-107 also stains white matter, resentative photomicrographs from AD
albeit indistinctly in most cases. E, However, other miRNAs such as miR-24 show much more distinct glial profiles (arrows) in case 3 and nondemented case 1 described
white matter. F shows a probe for the control miR-204, which was chosen because it has low CNS expression on microarray but in Materials and Methods). In the AD
cases, miR-124 remained strongly exhas a low Tm. Scale bars: A, F, 1 mm; B–E, 100 m.
pressed in the surviving neurons, whereas
miR-107 levels were decreased. In contrast,
used, in comparison with nondemented patients (n ⫽ 5) and
in the nondemented controls, miR-107 signal was present at a
those with pure AD (n ⫽ 2; positive control). A statistically sigqualitatively higher level. These cases were different from the
nificant drop in miR-107 was not seen in the DLB cases. A onecases in Figure 1 or 5, thus providing cellular level insights, and
way Student’s t test for miR-107 levels in DLB versus nondeindependent replication.
mented brains was p ⬎ 0.29.
miR-107 and BACE1: bioinformatic predictions
Validation: Northern blots and in situ hybridization
Having identified miR-107 as the miRNA with the most signifiMicroarray results were validated and extended using Northern
cant expression decrease early in the progression of AD, we
blots and ISH. For initial post hoc validation Northern blotting
sought to determine whether this change would have any impact
(Fig. 2), we chose to evaluate the earlier stages of the disease
on AD-related genes including BACE1, BACE2, APP, and SNCA,
(nondemented with no pathology, nondemented with mild or
and others. We used the rna22 algorithm (Miranda et al., 2006) to
moderate pathology, and mildly cognitively impaired with modexamine the corresponding 3⬘-UTRs for potential miR-107 binderate pathology) because this is where the miR-107 decrease was
ing sites. This algorithm was chosen because rna22 does not rely
most significant and where the cellular populations are most
on cross-genome sequence conservation to report putative bindcomparable. The findings by Northern blot were consistent with
ing sites for the microRNA under consideration. Using the dethose on the microarray; a number of miRNAs showed increased
fault parameter settings (Miranda et al., 2006), rna22 identified
expression in the early progression of AD, but miR-107 levels
five binding sites for miRNA miR-107 in the 3⬘-UTR of BACE1
decrease beginning early in the pathological evolution of the
mRNA (Fig. 6 A). Taking into account additional experimental
disease.
evidence (discussed below), which indicates that BACE1 is differIn situ hybridization (Figs. 3-5) revealed that miR-107 is exentially expressed (upregulated) in AD, we also considered the
pressed strongly in human neurons, as we have shown miR-124
possibility that miRNAs other than miR-107 may be involved in
to be previously (Nelson et al., 2006). In addition, the miR-107
the regulation of this gene. Analysis of the 3⬘-UTR of BACE1
probe labels some cells that by morphology appear to be astrousing rna22 indicates that at least 25 microRNAs from among
cytes. However, other miRNAs such as miR-24 stain white matthose listed in Release 9 of miRBase (Griffiths-Jones, 2006) have
ter, which includes glial cells with far fewer neurons, more
three or more putative binding sites (Fig. 6 B). More than onestrongly than miR-107 does (Fig. 3 D, E). Different miRNAs aphalf of the miRNAs that rna22 predicts target BACE1 are expear to stain particular layering patterns in the hexalaminar isopressed in brain tissue; however, in view of our differential excortex of the superior and middle temporal (SMT) gyrus. Specifpression profiling studies, we decided to focus on the interactions
ically, ISH with a miR-124 probe labels the superficial (layers I/II)
between miR-107 and BACE1 for this first analysis. Detailed proand the deeper (layers IV/V) neuronal lamina. Even in relatively
vision of the predicted miRNA:mRNA pairings are presented as
advanced AD, the pattern of miR-124 ISH is maintained. In a
supplemental file 2 (available at www.jneurosci.org as suppledemented control brain with extensive cerebral amyloid angiopmental material). We also compared the predictions of rna22 to
athy, miR-107 showed an identical staining pattern with distinct
those made by Pictar (Krek et al., 2005) and TargetScan (Lewis et
superficial and deep layer staining. In contrast, in brain sections
al., 2003). Across all the algorithms, we found that the 3⬘-UTR of
with extensive AD pathology, miR-107 ISH still shows the supermost AD-related genes were not predicted to be targeted by miR-
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107 (data not shown). With regard to
BACE1, one of the five sites predicted by
rna22, BACE1 (NM_012104.3) 3⬘-UTR
between mRNA nucleotides 2208 and
2245, was also reported by PicTar and TargetScan, although the latter two predicted
the site would be recognized by the paralogous miRNAs including miR-16, which
have the identical seed sequence as miR107. The MREs predicted by the various
programs and their relative locations are
shown in Figure 6.
Correlating miRNA expression with
mRNA expression profiling microarrays
and Western blot results
Because numerous recent studies have
shown that changes in miRNA levels lead
to altered levels of mRNA targets (Lim et
al., 2005; Wang and Wang, 2006; Grimson
et al., 2007), we performed correlative
mRNA studies on a subset of the cases of
nondemented (n ⫽ 4), MCI (n ⫽ 4), and
AD (n ⫽ 3) brains using the same RNA
extracted from temporal cortex and used in
the miRNA microarray studies. The results
of these experiments with regard to BACE1
and miR-107 expression are shown in Figure 7. These experiments show a clear
trend: cases with lower miR-107 (which
tend to have more AD pathology) tend to
have higher BACE1 mRNA than cases with
higher miR-107 and vice versa. Separate,
independent one-way ANOVA results indicate that both the increase in BACE1
mRNA as well as the decrease in miR-107
levels were statistically significant ( p ⬍
0.05). For comparison purposes, we show
analogous results for presenilin (PSEN1)
and for miR-125b in which such trends
were absent (Fig. 7B).
Figure 4. ISH-stained cells and AD-type neuropathology each show cerebral cortical lamina-specific staining patterns in
Having performed miRNA- and human brains that differ between AD and control. These experiments were performed on superior and middle temporal gyri using
mRNA-related profiling on the same 11 to- sections cut at 25 m. Photomicrographs depict near-serial sections through the middle temporal gyri of three human brains;
tal RNA samples, we were able to also test pial surface is up. Thioflavine S shows green-fluorescent amyloid and neurofibrillary tangles. The top two cases were from AD
the correlation between the levels of in- brains, and the bottom was from a profoundly demented stroke patient (mini-mental status examination score, 0); demented
tronic miRNAs (such as miR-107 and the control case, Thioflavine S shows cerebral amyloid angiopathy (CAA) with amyloid in small blood vessels (pink arrows). Note that
paralogous miR-103s) and those of the the superficial layers (lamina II; arrowheads) appear relatively spared in AD brain; however, in AD brain the deeper layers (laminas
mRNAs of their “mother” genes. These re- IV/V; asterisks) are severely depleted for miR-107 (left) but not miR-124 (right). The deeper, miR-107-depleted laminas are
sults are shown in Table 2. The correlations vulnerable to AD pathology, compatible with the hypothesis that miR-107 depletion is associated with the development of AD
of expression were highest for both miR- pathology. Scale bar: Top left, 500 m (for photomicrographs).
107 and miR-103 to PANK3 ⬎ PANK1 ⬎
Validation: tissue culture miRNA recognition element studies
PANK2. This was surprising because miR-107 is present in
Guided by the computational predictions presented above, we
PANK1. Nonetheless, as with the correlations for other intronic
focused on the two MREs that were consistently predicted by at
miRNAs and their mother genes, as shown in Table 2, none was
least the rna22 and PicTar methods. Their sequences are desigstatistically significant.
nated B1 and B2, respectively (Fig. 8). Each of the two MREs was
mRNA and protein levels are frequently discrepant (Nelson and
subcloned separately into pRL-TK expression plasmids and asKeller, 2007). Hence, we performed post hoc studies of six additional
sessed in HeLa cells to determine its physiological relevance.
aged human patients that were diagnosed as nondemented, MCI, or
These experiments depend partly on endogenous miRNAs, and
AD, to correlate the expression of miR-107 and BACE1 protein as
miR-107 was originally described in a study of HeLa cells
detected by Northern and Western blots, respectively. These results
(Mourelatos et al., 2002). Figure 8 shows the two sites B1 and B2
are shown in Figure 7, C and D. These results show that, at the
highlighted and also shows the sequences used and the results of
protein level, as well as the mRNA level, a decrease of miR-107 and
an increase in BACE1 expression tend to be seen in AD brains.
two different experiments (n ⫽ 3 replicates each). A third exper-
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In situ hybridizaton: parahippocampal gyrus
Alzheimer’s disease--Case 3

Alzheimer’s disease-Case 3

MRE was dramatically reduced as result of endogenous let-7 expression in HeLa cells as seen previously (Kiriakidou et al., 2004).
Note that neither siR107 nor siR320 had any effect on the luciferase activity of lin28 reporter.

Discussion

miR-124

miR-107

Non-demented-Case1

Non-demented-Case 1

miR-124

miR-107

Figure 5. ISH on perirhinal gyrus comparing nondemented elderly control and AD on nearserial sections again shows that miR-107 levels are decreased in deep cortical lamina of AD
brain. These are from different patients from those in Figure 4, and the result was replicated on
other patients (see Results). Whereas miR-124 ISH signal remains strong in the neurons that
survive AD neurodegeneration, miR-107 signal is qualitatively lower in neurons in AD brain. In
contrast, in the nondemented elderly controls, both the neuronal miR-107 and miR-124 ISH
signals are more robust. Scale bar, 500 m (for all four photomicrographs).

iment (n ⫽ 3 replicates) showed the same result (data not
shown). To establish valid negative controls for particular MRE
sequences, we scrambled the seed region sequences of the B1 and
B2 MREs, without changing the A/G/C/T content of the plasmid.
The highly similar control sequences were subcloned into separate pRLTK plasmids. Compared with the control sequences, the
reporter assays showed that Rluc activity of the reporter carrying
B1 MRE was clearly reduced as the result of endogenous miRNAs
(Student’s t test, p ⬍ 0.0001). This reduction was further augmented by the addition of miR107 siRNAs, indicating the specificity of miR-107 action on this MRE. To confirm that siR107
action is specific, the unrelated siR320 was included in the experiment. Addition of siR320 did not further decrease Rluc activity
as observed with siR107, but increased luciferase activity relative
to control, which may indicate a separate regulatory mechanism
or a possible compromise of miRNA function. Unlike MRE B1,
the subcloning of MRE B2 into the 3⬘-UTR of pRLTK did not
have any effect on Rluc activity, suggesting that B2 putative MRE
is probably not an miRNA recognition element or that it acts as a
MRE only in a specific context. In these experiments, the very
strong lin-28 MRE recognized by endogenous let-7 miRNAs and
its scrambled M2 were used as controls to monitor the reporter
assay system. The activity of the luciferase reporter bearing lin-28

miR-107 levels are decreased in human cerebral cortical gray
matter early in the pathological progression of AD, as shown by
expression profiling using microarrays and Northern blots. In
situ hybridization on human cerebral cortex demonstrated that
miR-107 is strongly expressed in neurons with a characteristic
laminar expression pattern. Bioinformatics approaches predict
that as many as five different sites on the 3⬘-UTR of BACE1
mRNA may be targeted by miR-107. Luciferase reporter assays
directly support the hypothesis that miR-107 regulates BACE1
through at least one discrete 3⬘-UTR MRE. Together, these data
indicate that the change in neuronal miR-107 expression contributes to the pathogenesis of AD.
There are several limitations to our data. The microarray we
used was unable to differentiate specifically between the paralogs
miR-103 and miR-107, which differ by a single nucleotide near
their 3⬘ ends. Nonetheless, the signal levels referent to miR-107
spots were consistently higher than miR-103 on the arrays, suggesting that miR-107 (and not miR-103) was likely the predominant miRNA detected. In any case, because of their extreme
sequence identity and the location of their single-nucleotide difference, the target prediction algorithms would have generated
the same list of putative binding sites. Previous studies have indicated that miRNA hybridization is not specific to the level of a
single-nucleotide difference at that part of the molecule (Kiriakidou et al., 2004; Goff et al., 2005). However, this issue will be
addressed in the immediate future. We also were surprised to find
a very low detection of miR-9 on this microarray platform. We
found discrepancies previously in miR-9 detection, which were
not linked to our microarray platform, and may indicate inherent
difficulty in phosphorylating or ligating to the UCUUU 5⬘ sequence of miR-9 (data not shown). Notwithstanding this technical shortcoming, the total number of miRNAs expressed above
background is quite compatible with the previous findings of
other brain miRNA microarray studies (Baskerville and Bartel,
2005; Gaur et al., 2007; Tang et al., 2007).
In addition to potential cross-reaction on this specific microarray platform, there are other caveats that pertain to most
human studies. When performing human brain studies, controlling for all relevant variables is virtually impossible. In the current
study, we included important non-AD dementia controls,
namely DLB. Nonetheless, it is possible that different patient
groups will be treated subtly differently, or manifest distinct comorbidities and/or behaviors that cause different environmental
conditions (such as circadian rhythms and agonal states/medicines) that might induce bias in miRNA expression patterns.
Our results indicate a regulatory mechanism involving molecules, miR-107 and BACE1, heretofore not known to interact.
Between those molecules, far less is known about miR-107. The
nearly identical paralogs miR-107 and miR-103 (Mourelatos et
al., 2002) (miR-103/7) have been shown to be expressed in many
mammalian organs with highest concentration in brain tissue
(Babak et al., 2004; Baskerville and Bartel, 2005; Wang and Wang,
2006). miR-103/7 are differentially expressed in a number of contexts, including during development (Esau et al., 2004; Miska et
al., 2004), neoplastic transformation (Roldo et al., 2006), hypoxia
(Kulshreshtha et al., 2007), and both cold and heat stress (Marsit
et al., 2006; van Rooij et al., 2006).
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Intriguingly, miR-107 expression may
relate to the coordinated regulation of a
pathway related to lipid metabolism (Wilfred et al., 2007). The DNA templates for
miR-107 and miR-103 each exist within introns in the genes that encode the pantothenate kinase (PANK) enzymes. In humans, there are at least three highly
homologous PANK genes. miR-103(1),
miR-103(2), and miR-107 reside within
PANK3, PANK2, and PANK1 genes, respectively (Ying and Lin, 2005). The basic
arrangement of these miRNAs in PANK
genes remains constant through 500 million years of vertebrate evolution (Wilfred
et al., 2007). PANK enzymes serve a universal catalytic function, namely, the phosphorylation of pantothenate (vitamin B5)
(Tahiliani and Beinlich, 1991). This is the
rate-limiting step in generating coenzyme
A (CoA), and PANKs are central enzymes
in the regulation of cellular CoA levels
(Leonardi et al., 2005). CoA is a necessary
cofactor in ⬃4% of known enzymes, including ⬎100 reactions involved in metabolism (Leonardi et al., 2005).
The location of miR-103/7 genes within
introns of the PANK genes may be physiologically relevant. Expression levels of in- Figure 6. A, A graphic depiction of BACE1 3⬘-UTR sequence showing the location of the MREs that were predicted by rna22 and
several other public-access miRNA target prediction databases. The asterisk denotes sequences that were predicted to be recogtronic miRNAs and their host genes are in
nized by homologous miRs (miR-15 family) that share the same seed sequence as miR-107. B, A partial list of microRNAs that
some but not all circumstances well corre- rna22 predicts target the BACE1 3⬘-UTR; note that the list includes only microRNAs that are predicted to target the BACE1 3⬘-UTR
lated, presumably because they are co- at three or more sites. Also shown are the starting locations for the five miR-107 binding sites that are predicted by rna22.
transcribed by RNA polymerase II
(Baskerville and Bartel, 2005; Ying and Lin,
experimental evidence, using reporter constructs with subcloned
2005, 2006); however, we find that in our comparison of miRNA
MREs in HeLa cells, corroborates the computational predictions
and mRNA microarrays, the correlations for intronic miRNAs
that endogenous miR-107 participates in the regulation of
and mother mRNAs was (from a statistical standpoint) nonexistBACE1. These reporter constructs have been useful in previous
ent. We speculate that the downstream miRNA processing is difdescription of miRNA:mRNA interactions (Kiriakidou et al.,
ferentially regulated, or, conceivably, these intronic miRNAs may
2004, 2005, 2007; Nelson et al., 2004). Our data suggest that at
be transcribed separately from the mRNAs. Additional work releast one of the putative miR-107 MREs is physiologically relemains to be performed in terms of the regulation of processing in
vant, albeit less potent than the very strongly inhibitory let-7
the context of intronic miRNAs.
MRE. Previous studies have supported a role for miRNAs in biBACE1 cleaves the ␤-amyloid precursor protein creating the
ologically important partial, as opposed to complete, suppression
neurotoxic ␤-amyloid peptide A␤1– 42 (Vassar et al., 1999; Haniu
of target mRNAs (Sevignani et al., 2006; Ying et al., 2006; Li et al.,
et al., 2000). The dysregulation of BACE1 appears to directly
2007).
contribute to the pathogenesis of AD (Dominguez et al., 2004;
BACE1 genetic regulation is complex (Preece et al., 2003; LaDurham and Shepherd, 2006; Guo and Hobbs, 2006; John, 2006).
hiri
et al., 2006; Li et al., 2006; Rossner et al., 2006; Mihailovich et
Our ISH show that miR-107, like BACE1 (Bigl et al., 2000; Fukual.,
2007;
Stockley and O’Neill, 2007; Tesco et al., 2007) and has
moto et al., 2002), is enriched in neurons. A striking laminar
been
shown
to occur partly posttranscriptionally (Marambaud et
staining pattern is observed for miRNAs miR-107, miR-124, and
al., 1998; Rossner et al., 2006). Different regulatory mechanisms
AD neuropathology alike. Laminas with evident decreased miRprobably overlap in time and in cytoplasmic domains with mul107 relative to miR-124 signal are vulnerable to developing AD
tiple transcriptional, translational, and posttranslational propathology. This correlation is by no means proof of the hypothcesses involved in BACE1 regulation. Because a pharmacological
esis that decreases in miR-107 levels cause increased vulnerability
regulation of BACE1 endopeptidase activity at its active site has
to AD. Nonetheless, it is suggestive and demonstrates the imporproved a challenge (Beher and Graham, 2005; Hull et al., 2006;
tance of complementing tissue-level profiling modalities with
Ohno, 2006), each of these regulatory mechanisms represent an
ISH.
alternative potential “handle” for altering BACE1 expression
Our computational analyses indicate that miR-107 may target
pharmacologically.
BACE1 mRNA posttranscriptionally through as many as five disPrevious studies have suggested roles for miRNAs in neurotinct binding sites in the 3⬘-UTR. One of these five sites was
degenerative disease. Recent reviews have summarized these data
common across three different target prediction algorithms.
(Hebert and De Strooper, 2007; Nelson and Keller, 2007; Singh,
However, it is entirely likely that the action of miR-107 on BACE1
2007). One previous study has shown that particular miRNAs are
is also effected by one or more of the other predicted sites. Indeed,
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Figure 8. A, Tissue culture validation was performed using HeLa cells to demonstrate
whether two of the putative MRE sequences predicted by multiple algorithms on BACE1 are
recognized physiologically by miR-107. These results indicate that, of the two tested putative
MREs, one (B1) is physiologically relevant but not the other (B2). B, For this experiment, six
different MREs were subcloned into pRLTK expression plasmids, along with PGL-3 control plasmids, to understand whether the MREs (designated B1 and B2) are changed as a result of
endogenous miRNAs. Furthermore, siRNAs were transfected that mimic miRNAs. B1 and B2
each were compared versus appropriate controls that were matched except for a small shifting
of nucleotides at the predicted seed-pair region. In addition, known positive and negative
controls were used, namely LIN-28 and M2, the former a very strong MRE recognized by endogenous let-7 miRNAs as described previously (Kiriakidou et al., 2004, 2005). Luciferase experiment results are presented in C. The bar signals shown to the right are the result of six different
experiments (n ⫽ 3 performed twice); the signals represent the Renilla luciferase signal that
has been normalized using the Firefly luciferase as a transfection efficiency control. Note that
miR-107 siRNAs cause a statistically significant additional drop in the reporter construct expression, but miR-320 actually caused an apparent lack of inhibition on the B1 MRE. For C, Student’s
t tests were performed. ##p ⬍ 0.0001; #p ⬍ 0.01. For the siR-107 experiments, # refers to the
statistical significance of the difference in the overall reporter decrease with, versus without,
siR-107 transfection.
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